“We believe that the lectin pathway plays a critical role in brain injury as evidenced by our published data showing that Omeros’ MASP-2 inhibitor OMS721 significantly reduced brain infarct size and ...

Omeros’ lead lectin pathway inhibitor YARTEMLEA ®, which inhibits the pathway’s effector enzyme MASP-2, is FDA-approved for the treatment of hematopoietic stem cell transplant-associated thrombotic ...

Omeros (OMER) announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting ...

The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® (narsoplimab-wuug), the first and only therapy indicated for ...